{"id":826245,"date":"2025-03-17T08:06:10","date_gmt":"2025-03-17T12:06:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/"},"modified":"2025-03-17T08:06:10","modified_gmt":"2025-03-17T12:06:10","slug":"mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/","title":{"rendered":"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo"},"content":{"rendered":"
\n

RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology\u2019s Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025.<\/p>\n

\n
\n Details for the Late-Breaking Clinical Trial Abstract:<\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Abstract Title:<\/td>\nEfficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension On A Standardized Antihypertensive Medication Regimen<\/td>\n<\/tr>\n
Presenter:<\/td>\nLuke Laffin, Advance-HTN Investigators, Cleveland Clinic Foundation<\/td>\n<\/tr>\n
Session Date\/Time:<\/td>\nSaturday, March 29th<\/sup> from 1:45 p.m. to 1:55 p.m. CT<\/td>\n<\/tr>\n
Session Title:<\/td>\nLate-Breaking Clinical Trials III (Session 104)<\/td>\n<\/tr>\n
Session Location:<\/td>\nMain Tent, North Hall B<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About Lorundrostat<\/strong>\n <\/p>\n

Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN) as well as chronic kidney disease (CKD). Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects.<\/p>\n

In a Phase 2, proof-of-concept trial (Target-HTN) in uncontrolled or resistant hypertensive subjects, once-daily lorundrostat demonstrated clinically meaningful blood pressure reduction in both automated office blood pressure measurement and 24-hour ambulatory blood pressure monitoring. Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia.<\/p>\n

\n About Mineralys<\/strong>\n <\/p>\n

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https:\/\/mineralystx.com<\/a>. Follow Mineralys on LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company\u2019s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company\u2019s expectation that Advance-HTN and Launch-HTN may serve as pivotal trials in any submission of a new drug application (NDA) to the United States Food and Drug Administration (FDA); the Company\u2019s ability to evaluate lorundrostat as a potential treatment for CKD, uHTN, rHTN or OSA in patients with hypertension; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of patients in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and\/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading \u201cRisk Factors\u201d in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n

\n Contact:<\/strong>
\n
\n Investor Relations<\/strong>
\n
\n investorrelations@mineralystx.com<\/a>
\n \n <\/p>\n

\n Media Relations<\/strong>
\n
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email:\u00a0tweible@elixirhealthpr.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology\u2019s Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025. Details for the Late-Breaking Clinical Trial Abstract: \u00a0 \u00a0 Abstract Title: Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled … <\/p>\n

Continue reading “Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826245","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology\u2019s Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025. Details for the Late-Breaking Clinical Trial Abstract: \u00a0 \u00a0 Abstract Title: Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled … Continue reading "Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-17T12:06:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo\",\"datePublished\":\"2025-03-17T12:06:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/\"},\"wordCount\":892,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/\",\"name\":\"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==\",\"datePublished\":\"2025-03-17T12:06:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/","og_locale":"en_US","og_type":"article","og_title":"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo - Market Newsdesk","og_description":"RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology\u2019s Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025. Details for the Late-Breaking Clinical Trial Abstract: \u00a0 \u00a0 Abstract Title: Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled … Continue reading \"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-17T12:06:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo","datePublished":"2025-03-17T12:06:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/"},"wordCount":892,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/","name":"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==","datePublished":"2025-03-17T12:06:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTAzOSM2ODA3NzE4IzUwMDExMzcwMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mineralys-therapeutics-announces-data-from-the-phase-2-advance-htn-trial-of-lorundrosat-for-the-treatment-of-hypertension-has-been-accepted-as-a-late-breaking-presentation-at-the-2025-american-college\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology\u2019s Annual Scientific Session & Expo"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826245"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826245\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}